Login to Your Account



Seeks to Out-License Xcytrin

Pharmacyclics Cuts Staff, Shifts Focus to Early Stage Candidates

By Jennifer Boggs


Monday, March 3, 2008
In the wake of the FDA's second rejection of non-small-cell lung cancer candidate Xcytrin, Pharmacyclics Inc. is slashing its work force by 40 percent and refocusing resources on its earlier-stage pipeline in cancer and immune-mediated diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription